#Sweden #Stockholm #Warrants #SciBase #Rights Issue

SciBase Updates Warrants of Series TO 2

SciBase Holding AB, a pioneer in dermatological medical technology, has recently announced significant changes concerning its series TO 2 warrants. This announcement follows a capital raise initiative that SciBase introduced in April 2024, aimed at enhancing its operational capabilities and expanding its innovative healthcare solutions.

The recalculation applies to the warrants that have been issued as part of the company's financing strategies. Effective from the recent rights issue concluded on December 29, 2025, SciBase has adjusted the terms of its series TO 2 warrants. Post-recalculation, each warrant entitles its holder to subscribe to 1.09 new shares at a subscription price of SEK 0.38 each. This adjustment is in line with the company's commitment to provide fair opportunities for exercising these financial instruments amidst evolving market conditions.

In an essential update, it has been confirmed that the last trading day for the BTA (BTA refers to the interim shares issued during rights issues) associated with this rights offering will now be February 9, 2026. This decision is pivotal, as it dictates the timeline within which existing and potential investors can engage with these financial instruments. Further movements regarding the conversion of BTA into shares are set for February 16, 2026. On this date, the shares resulting from the TO 2 warrants will also be delivered, marking a crucial financial event for the company and its stakeholders.

Notably, SciBase observed a significant uptake concerning its TO 2 warrant buyback offer, with 418,150,952 warrants accepted, which represents about 83.9% of all available warrants. This uptake indicates strong investor confidence in SciBase’s future prospects and its business model, which focuses on leveraging advanced technology for timely skin health management. Following this response, the outstanding warrants now total 80,383,883, positioning SciBase to potentially raise approximately SEK 33.3 million once all warrants are fully exercised. In doing so, the company's share capital will enhance by SEK 4,380,921.60 through the issuance of 87,618,432 new shares.

Such movements in the market reflect a broader trend where companies are adjusting their financial strategies to safe confines while ensuring investor engagement. The terms surrounding these changes, including any future alterations prompted by additional share issues, can be accessed via SciBase’s official website, keeping transparency at the forefront.

As a global leader in the dermatology sector, SciBase is continually building on over 20 years of research and innovation stemming from the Karolinska Institute in Stockholm, Sweden. The company is committed to enhancing patient care through its advanced Nevisense platform, which integrates artificial intelligence and electromagnetic impedance spectroscopy technology to deliver high accuracy in skin diagnostics. This commitment not only reduces healthcare costs but also strives to minimize patient suffering through timely interventions.

For further details or inquiries, interested parties can reach out directly to Pia Renaudin, the CEO of SciBase, at +46732069802 or via email at [email protected]. As the company moves forward, many will be keenly observing how these recalibrations will influence its stock performance and business trajectories in the medical technology landscape.

Established on the Nasdaq First North Growth Market since June 2, 2015, SciBase remains dedicated to its vision of advancing dermatological practices and improving the quality of life for patients dealing with skin-related health issues. To stay updated on the latest developments or access financial reports, visit their investor relations page.